Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 101

1.

Pharmacological chaperones in the age of proteomic pathology.

Small SA.

Proc Natl Acad Sci U S A. 2014 Aug 26;111(34):12274-5. doi: 10.1073/pnas.1413111111. Epub 2014 Aug 13. No abstract available.

PMID:
25122676
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Potential pharmacological chaperones targeting cancer-associated MCL-1 and Parkinson disease-associated α-synuclein.

Oh M, Lee JH, Wang W, Lee HS, Lee WS, Burlak C, Im W, Hoang QQ, Lim HS.

Proc Natl Acad Sci U S A. 2014 Jul 29;111(30):11007-12. doi: 10.1073/pnas.1320556111. Epub 2014 Jul 14.

PMID:
25024216
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Applying chaperones to protein-misfolding disorders: molecular chaperones against α-synuclein in Parkinson's disease.

Chaari A, Hoarau-Véchot J, Ladjimi M.

Int J Biol Macromol. 2013 Sep;60:196-205. doi: 10.1016/j.ijbiomac.2013.05.032. Epub 2013 Jun 5. Review. Erratum in: Int J Biol Macromol. 2014 Jul;68:274.

PMID:
23748003
[PubMed - indexed for MEDLINE]
4.

Molecular chaperones and co-chaperones in Parkinson disease.

Dimant H, Ebrahimi-Fakhari D, McLean PJ.

Neuroscientist. 2012 Dec;18(6):589-601. doi: 10.1177/1073858412441372. Epub 2012 Jul 24. Review.

PMID:
22829394
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Snaring the function of alpha-synuclein.

Bonini NM, Giasson BI.

Cell. 2005 Nov 4;123(3):359-61.

PMID:
16269324
[PubMed - indexed for MEDLINE]
Free Article
6.

Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson's disease.

Murphy KE, Gysbers AM, Abbott SK, Tayebi N, Kim WS, Sidransky E, Cooper A, Garner B, Halliday GM.

Brain. 2014 Mar;137(Pt 3):834-48. doi: 10.1093/brain/awt367. Epub 2014 Jan 28.

PMID:
24477431
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Pathogenesis of Parkinson's disease: emerging role of molecular chaperones.

Bandopadhyay R, de Belleroche J.

Trends Mol Med. 2010 Jan;16(1):27-36. doi: 10.1016/j.molmed.2009.11.004. Epub 2009 Dec 24. Review.

PMID:
20036196
[PubMed - indexed for MEDLINE]
8.

Hsp70 molecular chaperones and Parkinson's disease.

Witt SN.

Biopolymers. 2010 Mar;93(3):218-28. doi: 10.1002/bip.21302. Review.

PMID:
19768775
[PubMed - indexed for MEDLINE]
9.

What's to like about the prion-like hypothesis for the spreading of aggregated α-synuclein in Parkinson disease?

Dunning CJ, George S, Brundin P.

Prion. 2013 Jan-Feb;7(1):92-7. doi: 10.4161/pri.23806. Epub 2013 Jan 1. Review.

PMID:
23360753
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

The mitochondrial chaperone protein TRAP1 mitigates α-Synuclein toxicity.

Butler EK, Voigt A, Lutz AK, Toegel JP, Gerhardt E, Karsten P, Falkenburger B, Reinartz A, Winklhofer KF, Schulz JB.

PLoS Genet. 2012 Feb;8(2):e1002488. doi: 10.1371/journal.pgen.1002488. Epub 2012 Feb 2.

PMID:
22319455
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Alpha-synuclein and Parkinson's disease.

Lücking CB, Brice A.

Cell Mol Life Sci. 2000 Dec;57(13-14):1894-908. Review.

PMID:
11215516
[PubMed - indexed for MEDLINE]
12.

alpha-synuclein degradation by autophagic pathways: a potential key to Parkinson's disease pathogenesis.

Xilouri M, Vogiatzi T, Vekrellis K, Stefanis L.

Autophagy. 2008 Oct;4(7):917-9. Epub 2008 Oct 26.

PMID:
18708765
[PubMed - indexed for MEDLINE]
Free Article
13.

Chaperone-like activities of alpha-synuclein: alpha-synuclein assists enzyme activities of esterases.

Ahn M, Kim S, Kang M, Ryu Y, Kim TD.

Biochem Biophys Res Commun. 2006 Aug 11;346(4):1142-9. Epub 2006 Jun 13.

PMID:
16796993
[PubMed - indexed for MEDLINE]
14.

Molecular chaperones, α-synuclein, and neurodegeneration.

Witt SN.

Mol Neurobiol. 2013 Apr;47(2):552-60. doi: 10.1007/s12035-012-8325-2. Epub 2012 Aug 25. Review.

PMID:
22923346
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Amyloid fibril formation of alpha-synuclein is accelerated by preformed amyloid seeds of other proteins: implications for the mechanism of transmissible conformational diseases.

Yagi H, Kusaka E, Hongo K, Mizobata T, Kawata Y.

J Biol Chem. 2005 Nov 18;280(46):38609-16. Epub 2005 Sep 14.

PMID:
16162499
[PubMed - indexed for MEDLINE]
Free Article
16.

Structural changes in alpha-synuclein affect its chaperone-like activity in vitro.

Kim TD, Paik SR, Yang CH, Kim J.

Protein Sci. 2000 Dec;9(12):2489-96.

PMID:
11206070
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Alpha-synuclein and Parkinson's disease: a proteomic view.

Fasano M, Lopiano L.

Expert Rev Proteomics. 2008 Apr;5(2):239-48. doi: 10.1586/14789450.5.2.239. Review.

PMID:
18466054
[PubMed - indexed for MEDLINE]
18.

Proteome response to the panneural expression of human wild-type alpha-synuclein: a Drosophila model of Parkinson's disease.

Xun Z, Kaufman TC, Clemmer DE.

J Proteome Res. 2008 Sep;7(9):3911-21. doi: 10.1021/pr800207h. Epub 2008 Aug 7.

PMID:
18683964
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Molecular chaperones and associated cellular clearance mechanisms against toxic protein conformers in Parkinson's disease.

Hinault MP, Farina-Henriquez-Cuendet A, Goloubinoff P.

Neurodegener Dis. 2011;8(6):397-412. doi: 10.1159/000324514. Epub 2011 Mar 16. Review.

PMID:
21411979
[PubMed - indexed for MEDLINE]
20.

Could a loss of alpha-synuclein function put dopaminergic neurons at risk?

Perez RG, Hastings TG.

J Neurochem. 2004 Jun;89(6):1318-24. Review.

PMID:
15189334
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk